Reminder: Expert Access: Barclays Hosted KOL Call: Alzheimer's Disease Treatment Dynamics & Emerging Innovations (Reads to BIIB, LLY, BMY, ROP, UCB, LUN)

Research evidence excerpt

Reminder: Expert Access: Barclays Hosted KOL Call: Alzheimer's Disease Treatment Dynamics & Emerging Innovations (Reads to BIIB, LLY, BMY, ROP, UCB, LUN)

•• UCB SA: Alzheimer's data fails primary endpoint, but secondary endpoints suggest drug is

not yet dead (11/01/24)

Meet the Speaker

Jeffrey Maneval, MD, is the Director of Cognitive Neurology at MaineHealth (07/2025-

present) and previously served as an Assistant Professor of Neurology at the University of

Pennsylvania Perelman School of Medicine (09/2022-07/2025). He completed fellowship

training in behavioral neurology with an emphasis on Alzheimer's disease and the related

diseases, the mind-body connection, and the links between neurologic and psychiatric

illnesses.

His clinical interests are in Alzheimer's disease, anterograde amnesia, behavioral issues in

dementia, chronic traumatic encephalopathy, cognitive impairment, corticobasal

syndrome, dementia with Lewy bodies, expressive language disorder, frontal lobe

disinhibition, memory loss, mild cognitive impairment, and neurodegenerative diseases.

Meet the Analysts

Emily Field, CFA is a Director and Head of U.S.

Biopharmaceuticals equity research at Barclays. Joining

the bank’s London office in 2017, she previously served as

Head of the European Pharmaceuticals team, earning a #4

individual ranking in European Pharmaceuticals &

Biotechnology in the 2025 Extel survey. With more than

two decades experience across both buy-side and sell-side

roles, she has worked across multiple investing strategies

including risk arbitrage and equity long/short. Prior to

Barclays, Ms. Field held positions at UBS O’Connor and

Millennium Management. Originally hailing from Chicago,

Ms. Field holds a B.A. in Economics and History from Yale